L1, β-Catenin, and E-Cadherin Expression in Patients With Colorectal Cancer: Correlation With Clinicopathologic Features and Its Prognostic Significance

Objective: Currently, there are no clinically used/routine biomarkers that accurately predict whether colorectal cancer (CRC) patients will or will not respond to adjuvant chemotherapy The aim of this study was to invest gate L 1, beta-catenin. and E-cadherin expression In patients with CRC and their relationship to tumor progression and to identify patients who will respond to chemotherapy Methods: A total of 142 patterns who underwent surgical treatment for CRC were chosen retrospectively The sample; from these patients were analyzed by immunohistochemistry SPSS-14 program package was used for statistical calculation Results: Expression of L1. beta-catenin. and E-cadherin were found to be strongly associated with invasion and metastasis of CRC Cox multivariate analysis results indicated that 1,1 expression and stage of Dukes could be considered as the independent prognostic factors for survival Furthermore, our study found that the 5-year sin vival rate was the significantly associated with the expression of L1, beta-catenin (normal and ectopic expression). and E-cadherin for Dukes' stage B (P < 0 01) patients However. no such result was found for Dukes' stage A (P > 0 05) and C (P > 0 05) patients Conclusion: Our study provided reference tor identifying patients who need adjuvant chemotherapy L1, beta-catenin. and E-cadherin could he considered as biomarkers to predict whether CRC patients will or will not respond to adjuvant chemotherapy J Surg Oncol 2010:102 433-442 (C) 2010 Wiley-Liss. Inc